XBiotech Halts Rheumatology Program After Major Data Irregularities Found in Phase 2 Trial
XBiotech suspended its rheumatology program after its Phase II study of Natrunix for Rheumatoid Arthritis failed to meet the ACR20 response rate primary endpoint and revealed significant irregularities, including multiple enrollments of the same subjects at high-enrolling sites. Planned studies in arthritis and ankylosing spondylitis are now on hold.
Related News
XBiotech Halts Rheumatology Program After Major Data Irregularities Found in Phase 2 Trial
XBiotech suspended its rheumatology program after its Phase II study of Natrunix for Rheumatoid Arthritis failed to meet the ACR20 response rate primary endpoint and revealed significant irregularities, including multiple enrollments of the same subjects at high-enrolling sites. Planned studies in arthritis and ankylosing spondylitis are now on hold.